Clinical Endocrinology Update 2018: Anaheim

Garden Grove, CA US

Welcome to Clinical Endocrinology Update 2018!

The field of endocrinology is constantly evolving. Clinical Endocrinology Update (CEU) provides you with an opportunity to receive the latest updates in diagnosis and treatment options. Led by expert faculty, this 3-day meeting delivers a comprehensive endocrine program that emphasizes case-based learning to apply in practice. Presented in a variety of formats, including Meet-the-Professor sessions, lively debates, and panel discussions, CEU will provide you with the opportunity to learn from and network with faculty at the forefront of endocrine practice and research.


Seeking to claim MOC credits or get your CME certificate?

Use this form to complete the evaluation for the 2018 Clinical Endocrinology Update meeting and to claim MOC credits and a CME certificate.

After completing the evaluation form, a CME certificate will be displayed; please print or save this certificate for your records. You can log back in at any time to review your credit transcript and reprint the certificate.


If you attended Growth Hormone Deficiency: Diagnosis Challenges and Treatment Considerations on Sunday, October 21, claim your points below.

Growth Hormone Deficiency: Claim CME and MOC

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Men’s Health
Neuroendocrinology and Pituitary
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 21.50 ABIM MOC
  • 21.50 AMA PRA Category 1 Credits
  • 21.50 CME Certificate of Participation
Course opens: 
Course expires: 

Day 1 – Friday, October 19


7:00 AMContinental Breakfast
7:45–7:55 AMWelcome and Introduction
Janet A. Schlechte, MD
7:55–8:25 AM

Treatment Goals in Osteoporosis
E. Michael Lewiecki, MD

8:25–8:55 AMUpdate on the Management of Renal Bone Disease
Robert A. Wermers, MD
8:55–9:25 AMOsteoporosis: Answers to Patients' Questions
Ann E. Kearns, MD, PhD
9:25–9:55 AMHypophosphatemic Disorders and their Management
Suzanne M. Jan de Beur, MD
9:55–10:10 AMQ&A/Panel Discussion
10:10–10:25 AMCoffee Break / Exhibits
10:25–10:55 AMManagement of the Patient Before and After Bariatric Surgery
Christopher D. Still, DO
10:55–11:25 AMPharmacotherapy for Obesity
Marc-Andre Cornier, MD
11:25–11:55 AMUsing New and Emerging Therapies in Managing Hypercholesterolemia 
Alan Chait, MD
11:55 AM–12:10 PMQ&A/Panel Discussion
12:10–1:25 PMLunch/Exhibits
Optional Conference Events
12:20–1:15 PMPens, Pumps and Beyond: A Roundtable Discussion on Advances in Diabetes Technology
1:25–2:10 PMMeet-the-Professor Sessions
2:10–2:25 PMBreak/Exhibits
2:25–2:55 PMMenopausal Hormone Therapy and Alternatives
Margaret E. Wierman, MD
2:55–3:25 PMCase-Based Debate of Whether to Start Testosterone Therapy and How to Monitor
Panelists::ModeratorBradley D. Anawalt, MD
3:25–3:45 PMQ&A/Panel Discussion
3:45–4:00 PMCoffee Break / Exhibits
4:00–4:30 PMHyperandrogenic Anovulation: PCOS and Tumors
Margaret E Wierman, MD
4:30–5:00 PMObesity-Related Low Testosterone
Shehzad Basaria, MD
5:00–5:15 PMQ&A/Panel Discussion
5:15–5:20 PMBreak
5:20–6:05 PMMeet-the-Professor Sessions
(Sessions Repeat from Earlier)
6:05 PMAdjourn


Day 2 – Saturday, October 20


Day 1 | Day 2 | Day 3


7:00 AMContinental Breakfast
7:45–7:55 AMWelcome and Introduction
Janet A. Schlechte, MD
7:55–8:25 AMDiabetes and Heart Failure
Biykem Bozkurt, MD PhD
8:25–8:55 AMWhat’s New in Continuous Glucose Monitoring?
Anders Carlson, MD
8:55–9:25 AMRenal Outcomes and New Diabetes Medications
Mark E. Molitch, MD
9:25–9:45 AMQ&A/Panel Discussion
9:45–10:05 AMCoffee Break / Exhibits
10:05–10:35 AMWhat Next After Basal Insulin
Carol Wysham, MD
10:35–11:05 AMPros and Cons with Non-Insulin Therapies in Gestational Diabetes
Donald R. Coustan, MD
11:05–11:35 AMDiabete$: Patient$, Doctor$, Insurer$, Manufacturer$, and $ociety
Alvin C. Powers, MD
11:35–11:55 AMQ&A/Panel Discussion
11:55 AM–1:10 PMLunch/Exhibits
Optional Conference Events
12:00–1:00 PMAn Insulin Monotherapy Option for Patients on High Doses of Insulin
John Gilbert, MD | Director of Clinical Trials, St. Jude Heritage Medical Group Fullerton, California

The program is about a concentrated human insulin indicated to improve glycemic control for specific patients. Discuss a hypothetical patient case study as a means to identify appropriate candidates, review the efficacy and safety profile, and go over how to initiate and titrate patients on this insulin monotherapy regimen. Sponsored by Lilly USA, LLC (Non-CME Program)

1:10–1:55 PMMeet-the-Professor Sessions
1:55–2:05 PMBreak
2:05–2:35 PMCongenital Adrenal Hyperplasia: Diagnosis and Treatment
Richard Auchus, MD, PhD
2:35–3:05 PMAdrenal Fatigue and Failure: Fantasy and Facts
James Findling, MD
3:05–3:35 PMAdrenal Cases with Faculty Panel
3:35–3:55 PM Q&A/Panel Discussion
3:55–4:15 PMCoffee Break
4:15-5:00 PMMeet-the-Professor Sessions
(Sessions Repeat from Earlier)
5:00 PMAdjourn


Day 3 – Sunday, October 21


Day 1 | Day 2 | Day 3


7:00 AMContinental Breakfast
7:45–7:55 AMWelcome and Introduction
Janet A. Schlechte, MD
7:55–8:25 AMMedical Treatment of Acromegaly: A Stepwise Approach
Shlomo Melmed, MD
8:25–8:55 AMTreatment of Cushing Disease when Surgery Fails: Individualized Case-Based Approach
James Findling, MD
8:55–9:25 AMTreatment with Anti-PD-1/PD-L1 and Anti-CTLA-4 Drugs: Endocrine Side Effects
Laurence Katznelson, MD
9:25–9:40 AMQ&A/Panel Discussion
9:40–9:55 AMCoffee Break
9:55–10:40 AMMeet-the-Professor Sessions
10:40–10:50 AMBreak
10:50–11:20 AM Papillary Thyroid Microcarcinomas
Megan R. Haymart, MD
11:20–11:50 AMSubclinical Thyroid Disorders
Kristien Boelaert, MD, PhD
11:50 AM–12:05 PMQ&A/Panel Discussion
12:05–1:20 PMLunch
Optional Conference Event
12:15–1:15 PMGrowth Hormone Deficiency: Diagnosis Challenges and Treatment Considerations
Chair: Shlomo Melmed, MD
This program seeks to close knowledge and practice gaps among clinicians treating patients with growth hormone deficiency (GHD). In this program, Shlomo Melmed, MD and Craig Alter, MD will provide the latest information on ways to improve diagnosis and patient outcomes, approaches to selecting and optimizing growth hormone therapy, and growth hormone therapy transition controversies and strategies. 1.00 CME credits (No registration required)
1:20–2:05 PMMeet-the-Professor Sessions
(Sessions Repeat from Earlier)
2:05–2:10 AMBreak
2:10–2:40 PMOverview of Thyroid Nodules
Kevin T. Brumund, MD
2:40–3:25PMChallenging Thyroid Cases with Faculty
Kristien Boelaert, MD, PhD
Megan R. Haymart, MD
Kevin T. Brumund, MD
3:25–3:30 PMClosing
Janet A. Schlechte, MD


Hyatt Regency Orange County
11999 Harbor Blvd
Garden Grove, CA 92840
United States
+1 (714) 750-1234

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following steering committee members reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Whitney S. Goldner, MD (Incoming Chair):  Primary Investigator for Astra Zeneca and Eisai. Site Primary Investigator for Roche. Husband is a nephrologist and is medical director for dialysis units for Davita.

Daniel H. Bessesen, MD: Serve on the data safety monitoring committee for Enteromedics Inc.

Sigridur Bjornsdottir, MD, PhD: Advisory Group for Amgen; Research Support for Shire; and Speaker for Mylan and Shire.

Kathleen M. Dungan, MD, MPH: Receives research funding from Novo Nordisk, Merck, Sanofi Aventis, GlaxoSmithKline. Is a consultant for Eli Lilly, GSK, Sanofi Aventis, Novo Nordisk, Mannkind. Receives royalties from Up to Date. Participated in development of CME Activities (indirectly funded by Pharma) from Novo Nordisk, Jansen, Merck, Astra Zeneca, Sanofi Aventis.

Monica Gadelha, MD, PhD: Advisory Board for Novartis and Ionis. Received lectures fee from Novartis and Ipsen. Is a principal investigator in clinical trials for Novartis and Ipsen. Received unrestricted research grants from Ipsen and Pfizer.

Serge A. Jabbour, MD (EBR Chair): Consultant and on Advisory boards for AstraZeneca, Eli Lilly & Janssen.

Priyathama Vellanki, MD: Consultant for Merck & Co. and Boehringer Ingelheim. Co-Investigator on a study at Emory University that is funded by Boehringer Ingelheim.

The following steering committee members reported no relevant financial relationships: Janet A. Schlechte, MD, Chair; Richard A. Bebb, MD; Ann E. Kearns, MD, PhD; Tim Korevaar, MD, PhD; Connie Baum Newman, MD; Camille E. Powe, MD; and Jennifer A. Sipos, MD.


The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Andrew Ahmann, MS, MD: Consultant to Dexcom and Lilly. Institution receives research support from Medtronic.

John K. Amory, MD, MPH, MSc: Consultant and receives research funding from Clarus Therapeutics.

Richard Auchus, MD, PhD: Grant/Research/Clinical Trial Support: Strongbridge Biopharma; Novartis; Neurocrine Biosciences; Spurce Biosciences; Diurnal, LTD. Consultant/Advisory Boards: Millendo Therapeutics; Corcept Therapeutics; Janssen Pharmaceuticals; Quest Diagnostics; Novartis; Strongbridge Biopharma; Adrenas Therapeutics; Spruce Biosciences; Selenity Therapeutics.

Biykem Bozkurt, MD, PhD: Consultant for Bayer Pharmaceuticals, Lantheus Medical Imaging, Knowledge to Practice K2P Education. Site PI for PIONEER -Multicenter Randomized Trial of ARNI in  ADHF patients (Novartis)

Anders L. Carlson, MD: Advisory board member for Insulet. Consultant to Medtronic and Novo Nordisk. Receives research support from Dexcom, Medtronic, and Novo Nordisk.

James W. Findling, MD: Investigator/Consultant for Corcept, Novartis and Diurnal.

Korey Hood, PhD: Consultant to Insulet, Johnson & Johnson Diabetes Institute, and Lilly Innovation Center. Receives research support from Dexcom for an investigator-initiated study.

Suzanne M. Jan de Beur, MD: Receives research support and is on the advisory board for Ultragenyx. Is on the advisory board for XLH Network.

David Kerr, MBChB, DM, FRCPE: Medical advisor to Glooko and Vicentra. Advisory board member for Ascensia, Novo Nordisk, and Sanofi. Receives research support from Lilly.

E. Michael Lewiecki, MD: Institutional grant/research support from Amgen, Radius, PFEnex, and Mereo​; Scientific advisory boards for Amgen, Radius, Shire, Alexion, Ultragenyx, and Sandoz​; Speakers’ bureaus for Shire, Alexion, and Radius; Board positions with the ISCD, NOF, and OFNM​

Shlomo Melmed, MD: Consultant (Consulting Fee): Cliasma, Midatech, Ionis, Strongbridge and Primary Investigator (Research Grant):  Pfizer, IPSEN

Mark E. Molitch, MD: Received research support from NovoNordisk, Bayer, Janssen, Chiasma, and Novarits. Consultant for Merck, Pfizer, Ipsen, Chiasma, Novartis, and Janssen.

Joshua D. Safer, MD: My spouse is employed by Parexel as a contracts specialist.  Was on one advisory panel for Endo Pharmaceuticals in 2018.

Margaret E. Wierman, MD: Grant reviewer for Pfizer, pituitary investigator for grants for NovoNordisk, Corcept, Prolor, Novartis.

Carol Wysham, MD: Consultant/Advisor: Abbott, Janssen, Novo Nordisk, Sanofi. Speakers Bureau:  Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Janssen, Novo Nordisk, Sanofi.

The following faculty reported no relevant financial relationships: Bradley D. Anawalt, MD; Shehzad Basaria, MD, MBBS; Kristien Boelaert, MD, PhD; Kevin T. Brumund, MD; Alan Chait, MD; Marc-Andre Cornier, MD; Donald R. Coustan, MD; Megan R. Haymart, MD; Anne E. Kearns, MD, PhD;  Leo A. Kim, MD, PhD; Alvin C. Powers, MD; Janet A. Schlechte, MD; Christopher D. Still, DO; and Robert A. Wermers, MD

The following faculty will disclose any relevant financial relationships during their presentations: Jennifer A. Sipos, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

This program is supported by educational grants from AbbVie, Inc., Corcept Therapeutics, Inc., Ipsen Biopharmaceuticals, Lilly USA, Inc., Medtronic Diabetes, Novo Nordisk Inc., Pfizer, Radius Health, Inc., and TherapeuticsMD.

Click "Start" to complete meeting evaluation, claim CME & Maintenance of Certification (MOC) points, and print a certificate of attendance or certificate of participation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 21.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC):

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the responsibility of the Endocrine Society to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Verify Your ABIM MOC Eligibility

Log in then verify your profile details in the table below to confirm ABIM MOC eligibility.  If you see your name in the table below and other information is blank or incorrect, click the Review & Edit your Profile button to update and make changes.


My NameI am Certified by the ABIMMy ABIM NumberMy Date of Birth
[current-user:profile-profile:field-first-name] [current-user:profile-profile:field-last-name]




Review & Edit your Profile>



Available Credit

  • 21.50 ABIM MOC
  • 21.50 AMA PRA Category 1 Credits
  • 21.50 CME Certificate of Participation